Attovia Therapeutics files S-1 for IPO on Nasdaq under ticker ATTO

Attovia Therapeutics filed a registration statement with the SEC on July 14, 2026 for an initial public offering of common stock. The company has applied to list on the Nasdaq Global Market under the symbol "ATTO," with the offering contingent on that listing approval.

Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, built on its ATTOBODY biologics platform.¹ Its lead candidate, ATTO-1310, targets interleukin-31 and finished patient dosing in a Phase 1 trial covering both healthy volunteers and patients during the first quarter of 2026.¹ The company reported that ATTO-1310 has shown a favorable tolerability profile in healthy volunteers and patients with chronic pruritus and high-itch atopic dermatitis, with mostly Grade 1 or 2 treatment-emergent adverse events and no treatment-related serious adverse events, along with dose-proportional pharmacokinetics and no detectable neutralizing anti-drug antibodies.¹ Attovia said it expects to start a Phase 2 trial for ATTO-1310 in the first half of 2027.¹

The pipeline also includes ATTO-2306, a bispecific targeting IL-13 and IL-31 currently in IND-enabling studies, with a Phase 1 trial expected in the first half of 2027,¹ and ATTO-1091, a trispecific Fc fusion protein designed to block TL1A, IL-23 and integrin α4β7 simultaneously, also in IND-enabling studies.¹

On financing, Attovia disclosed that it has raised $255.8 million since inception as of March 31, 2026, from investors including Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives and venBio.¹ For the year ended December 31, 2025, the company reported a net loss of $60.6 million, compared with $39.8 million in 2024, and a net loss of $18.7 million for the three months ended March 31, 2026.¹ It had an accumulated deficit of $129.7 million as of March 31, 2026.¹ Underwriters on the offering include Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital.